Table 1 One-year prevalence (per 1000 inhabitants < 18 years of age) of psychotropic drug use among 0–17 year olds a; overall and in psychotropic drug subcategories, in the period 2004-2014
Boys | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 |
N= | 555,198 | 557,821 | 560,169 | 561,730 | 563,373 | 565,599 | 568,891 | 571,362 | 573,463 | 575,654 | 576,584 |
Alimemazine (R06DA01) | 8.3 | 7.1 | 7.0 | 7.0 | 5.8 | 5.7 | 6.3 | 5.6 | 4.9 | 4.4 | 4.5 |
Hypnotics/sedatives (N05C) | 4.2 | 5.3 | 6.1 | 7.3 | 7.9 | 8.7 | 9.5 | 10.0 | 10.1 | 10.1 | 10.8 |
Stimulants (N06BA) | 15.0 | 16.9 | 17.5 | 18.7 | 19.7 | 20.5 | 21.0 | 20.8 | 20.7 | 20.6 | 20.8 |
Antidepressants (N06A) | 2.1 | 1.7 | 1.7 | 1.8 | 1.8 | 2.0 | 2.2 | 2.2 | 2.2 | 2.1 | 2.0 |
Antipsychotics (N05A) | 1.6 | 1.8 | 1.9 | 2.0 | 2.2 | 2.3 | 2.3 | 2.4 | 2.3 | 2.2 | 2.2 |
Anxiolytics (N05B) | 4.7 | 4.8 | 4.9 | 4.9 | 4.5 | 4.6 | 4.6 | 4.7 | 4.6 | 4.2 | 3.9 |
Total psychotropics | 30.6 | 30.7 | 31.8 | 33.5 | 33.5 | 35.0 | 37.0 | 36.7 | 35.9 | 34.7 | 35.3 |
Girls | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 |
N= | 527,128 | 530,212 | 532,559 | 534,273 | 535,906 | 537,882 | 540,265 | 543,012 | 544,762 | 547,243 | 548,577 |
Alimemazine (R06DA01) | 7.1 | 6.4 | 6.4 | 6.4 | 5.3 | 4.9 | 5.5 | 5.5 | 5.1 | 4.6 | 4.7 |
Hypnotics/sedatives (N05C) | 2.6 | 3.2 | 3.7 | 4.4 | 5.1 | 5.7 | 6.4 | 7.0 | 7.7 | 8.0 | 8.8 |
Stimulants (N06BA) | 3.8 | 4.9 | 5.5 | 6.3 | 7.0 | 7.4 | 7.9 | 7.9 | 8.1 | 8.3 | 8.5 |
Antidepressants (N06A) | 3.1 | 2.5 | 2.4 | 2.6 | 2.6 | 2.6 | 2.8 | 3.0 | 3.6 | 4.0 | 10.0 |
Antipsychotics (N05A) | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.2 | 1.5 | 1.5 | 1.6 |
Anxiolytics (N05B) | 4.5 | 4.7 | 4.7 | 4.7 | 4.4 | 4.4 | 4.2 | 4.4 | 4.5 | 4.1 | 3.9 |
... Total psychotropics | 19.2 | 19.0 | 19.7 | 20.9 | 20.7 | 21.1 | 22.9 | 23.6 | 24.5 | 24.2 | 25.0 |